Atrium Therapeutics (RNA) Q4 2025 Earnings — Miss Estimates

Screener

Reported March 2, 2026 · Before market open

Revenue$859.0KMiss by $1.3M

EPS-$1.70Miss by $0.46

Revenue estimate$2.1M

EPS estimate-$1.24

Next report

Nov 12, 2026 (in 2 months)

Revenue estimate$15.0M

EPS estimate-$0.87

Versus estimates

Revenue

Q2 2026$3.0MBeat by $2.3M Q1 2026$19.6MBeat by $17.6M

Q4 2025$859.0KMiss by $1.3M

Diluted EPS

Q2 2026-$1.18Beat by $0.24 Q1 2026-$0.97Beat by $0.08

Q4 2025-$1.70Miss by $0.46

FAQ

When did Atrium Therapeutics report Q4 2025 earnings?: Atrium Therapeutics (RNA) reported Q4 2025 earnings on March 2, 2026 before market open.
What were Atrium Therapeutics's Q4 2025 revenue and EPS?: Atrium Therapeutics reported revenue of $859.0K and eps of $-1.70 for Q4 2025.
Did Atrium Therapeutics beat estimates in Q4 2025?: Revenue missed the consensus estimate of $2.1M by $1.3M. EPS missed the consensus estimate of $-1.24 by $0.46.
Where can I find Atrium Therapeutics's Q4 2025 SEC filings?: You can read the 8-K earnings release (0001193125-26-083227) directly on SEC EDGAR. The filing index links above go to sec.gov.

Ask the moment Atrium Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Harbor at dusk